Skip to content
Snippets Groups Projects
Commit 898748c7 authored by Timofej Paramonov Bliki's avatar Timofej Paramonov Bliki :heart:
Browse files

Main changes are padding and image adding. 

Fixed:
- Added the images necessary
- Changed the layout slightly
- Bigger font
- Added padding to the sides for larger screens
Need to fix:
- Image sizes on smaller screens - maybe use javascript?
- Save bigger font across entire wiki for readability
parent b7028952
No related branches found
No related tags found
1 merge request!4Main changes are padding and image adding.
Pipeline #388368 failed
Stage: build
Hide whitespace changes
Inline Side-by-side
wiki/pages/description.html
+ 81
− 53
View file @ 898748c7
......@@ -5,74 +5,102 @@
{% block page_content %}
<div class="row mt-4">
<div class="col-lg-8">
<p>The Radboud University iGEM team is dedicated to addressing the daily challenges faced by patients with hemophilia A. This condition is caused by a genetic mutation in the FVIII gene on the X-chromosome, which prevents liver sinusoidal endothelial cells (LSECs) from producing coagulation factor VIII, a crucial protein in the blood clotting process. Our project aims to develop a more effective and comfortable treatment for this genetic disorder compared to current methods.</p>
</div>
<div class="col-lg-4">
<p>Image eventually goes here.</p>
</div>
</div>
<style>
p {
font-size: 20px
}
</style>
<div class="row mt-4">
<div class="col-lg-8">
<p>We propose the creation of a niosome vesicle containing mRNAs that encode the coagulation factor VIII protein. These vesicles will be administered into the bloodstream, travel to the liver, and target LSECs with the help of surface proteins. Once inside the cells, the vesicles will release the mRNAs, leading to the production of coagulation factor VIII. This approach enables patients to produce their own coagulation factor VIII, eliminating the need for frequent injections of plasma-derived or recombinant proteins. A visual representation of the vesicle structure is provided below. </p>
</div>
<div class="col-lg-4">
<p>Image eventually goes here.</p>
<div class="px-lg-5">
<div class="row mt-4">
<div class="col-lg-8">
<p>
The Radboud University iGEM team is dedicated to addressing the daily challenges faced by patients with hemophilia A.
This condition is caused by a genetic mutation in the FVIII gene on the X-chromosome, which prevents liver sinusoidal endothelial cells (LSECs) from producing coagulation factor VIII, a crucial protein in the blood clotting process.
Our project aims to develop a more effective and comfortable treatment for this genetic disorder compared to current methods.
</p>
</div>
<div class="col-lg-4">
<img src="https://static.igem.wiki/teams/5342/images/description/desc1.jpg" alt="Hemophilia A" class="img-fluid">
</div>
</div>
</div>
<div class="row mt-4">
<div class="col-lg-8">
<p>Our innovative treatment aims to address significant issues with current hemophilia therapies. Presently, patients experience large fluctuations in blood coagulation factor VIII levels after injections, leading to brief stable periods followed by rapid declines. This necessitates frequent injections and risks sudden drops in coagulation factor VIII protein levels, which can trigger hemophilia symptoms. Our mRNA delivery system is expected to provide more stable and prolonged protein levels, reducing the frequency of treatments and associated anxieties.</p>
</div>
<div class="col-lg-4">
<p>Image eventually goes here.</p>
<div class="row mt-4">
<p>
We propose the creation of a niosome vesicle containing mRNAs that encode the coagulation factor VIII protein.
These vesicles will be administered into the bloodstream, travel to the liver, and target LSECs with the help of surface proteins.
Once inside the cells, the vesicles will release the mRNAs, leading to the production of coagulation factor VIII.
This approach enables patients to produce their own coagulation factor VIII, eliminating the need for frequent injections of plasma-derived or recombinant proteins.
A visual representation of the vesicle structure is provided below.
</p>
</div>
</div>
<div class="row mt-4">
<div class="col-lg-8">
<p>Additionally, our vesicle-based system offers an alternative to intravenous administration. Recognizing the discomfort of this method, we propose a nasal spray delivery system using hydrogel and vesicles, which allows mRNA absorption through the nasal epithelium. This method promises greater comfort for patients.</p>
</div>
<div class="col-lg-4">
<p>Image eventually goes here.</p>
<div class="row mt-4 d-flex justify-content-center align-items-center">
<img src="https://static.igem.wiki/teams/5342/images/description/desc2.png" alt="Vesicle structure" class="img-fluid w-50">
</div>
</div>
<div class="row mt-4">
<div class="col-lg-8">
<p>Another critical advantage of our approach is the elimination of the risk of viral infections, such as HIV and HCV, which can occur with human plasma-derived treatments. While rare, such infections are possible. By avoiding human-derived components, our treatment ensures safety from these risks.</p>
<div class="row mt-4">
<div class="col-lg-8">
<p>
Our innovative treatment aims to address significant issues with current hemophilia therapies.
Presently, patients experience large fluctuations in blood coagulation factor VIII levels after injections, leading to brief stable periods followed by rapid declines.
This necessitates frequent injections and risks sudden drops in coagulation factor VIII protein levels, which can trigger hemophilia symptoms.
Our mRNA delivery system is expected to provide more stable and prolonged protein levels, reducing the frequency of treatments and associated anxieties.
</p>
</div>
<div class="col-lg-4">
<img src="https://static.igem.wiki/teams/5342/images/description/desc3.png" alt="Graph that demonstrates rapid declines" class="img-fluid">
</div>
</div>
<div class="col-lg-4">
<p>Image eventually goes here.</p>
<div class="row mt-4">
<div class="col-lg-8">
<p>
Additionally, our vesicle-based system offers an alternative to intravenous administration.
Recognizing the discomfort of this method, we propose a nasal spray delivery system using hydrogel and vesicles, which allows mRNA absorption through the nasal epithelium.
This method promises greater comfort for patients.
</p>
</div>
<div class="col-lg-4">
<img src="https://static.igem.wiki/teams/5342/images/description/desc4.jpg" alt="Nasal spray" class="img-fluid w-50">
</div>
</div>
</div>
<div class="row mt-4">
<div class="col-lg-8">
<p>Hemophilia is a widespread condition affecting approximately 1,125,000 people worldwide and we, as a group of young scientists, are committed to enhancing the quality of life for these patients. In severe cases, hemophilia can lead to fatal blood loss, but even minor inconveniences, like restricted physical activities, significantly impact patients' lives. Our project aspires to contribute to a better quality of life for those affected by hemophilia, addressing both major and minor challenges of the current treatment landscape.</p>
<div class="row mt-4">
<div class="col-lg-8">
<p>
Another critical advantage of our approach is the elimination of the risk of viral infections, such as HIV and HCV, which can occur with human plasma-derived treatments.
While rare, such infections are possible.
By avoiding human-derived components, our treatment ensures safety from these risks.
</p>
</div>
<div class="col-lg-4">
<img src="https://static.igem.wiki/teams/5342/images/description/desc5.jpg" alt="Human holding heart, symbolically representing safety" class="img-fluid">
</div>
</div>
<div class="col-lg-4">
<p>Image eventually goes here.</p>
<div class="row mt-4">
<p>
Hemophilia is a widespread condition affecting approximately 1,125,000 people worldwide and we, as a group of young scientists, are committed to enhancing the quality of life for these patients.
In severe cases, hemophilia can lead to fatal blood loss, but even minor inconveniences, like restricted physical activities, significantly impact patients' lives.
Our project aspires to contribute to a better quality of life for those affected by hemophilia, addressing both major and minor challenges of the current treatment landscape.
</p>
</div>
</div>
<div class="row mt-4">
<div class="col">
<h2>Reference Articles:</h2>
<ol>
<li>Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver:
<br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7909888/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7909888/</a> </li>
<li>Systemic delivery of factor IX messenger RNA for protein replacement therapy:
<br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347596/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347596/</a> </li>
<li>Advanced Strategies for Overcoming Endosomal/Lysosomal Barrier in Nanodrug Delivery:
<br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208951/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208951/</a> </li>
</ol>
<div class="row mt-4">
<div class="col">
<h2>Reference Articles:</h2>
<ol>
<li>Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver:
<br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7909888/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7909888/</a> </li>
<li>Systemic delivery of factor IX messenger RNA for protein replacement therapy:
<br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347596/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347596/</a> </li>
<li>Advanced Strategies for Overcoming Endosomal/Lysosomal Barrier in Nanodrug Delivery:
<br><a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208951/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208951/</a> </li>
</ol>
</div>
</div>
</div>
<!-- This comment is to preserve the template description.html, which will be deleted once this file is complete.
<div class="row mt-4">
<div class="col">
......
0% or .
You are about to add 0 people to the discussion. Proceed with caution.
Finish editing this message first!
Please register or to comment